NEW YORK, NY / ACCESSWIRE / July 27, 2020 / Alpha Bronze, LLC ("Alpha Bronze"), is pleased to announce that Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, will be presenting at Alpha Bronze Virtual Town Hall on Wednesday, July 29, 2020 at 12:00 PM EDT.

Dr. Heman Chao, Chief Executive Officer of Helix will give an overview of the Company, its Lung Cancer and Pancreatic Cancer Clinical programs and upcoming milestones. Dr. Chao will respond to Investors questions thereafter.

Helix BioPharma – Town Hall Agenda

CEO Presentation – 10 to 15 minutes

Follow-up Q&A – 10 to 15 minutes

The presentation will be webcast live. You can access register to the Virtual Town Hall with the following link: https://zoom.us/webinar/register/WN_0tdX0OQrTuS_gJCk53zVTQ

REGISTER

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Helix is a biopharmaceutical company developing unique therapies in the field of immuno-oncology, for the prevention and treatment of cancer, based on its proprietary technology platform DOS47. Helix is currently listed on the TSX under the symbol "HBP". For more information: https://www.helixbiopharma.com.

About Alpha Bronze

Founded in 2013, Alpha Bronze is an investor relations firm based in New York. Alpha Bronze is dedicated to the delivery of top-tier strategic services that encompass IR, capital markets navigation, and corporate communications. The firm has an extensive experience working with emerging growth companies, in the life sciences, tech, consumer and natural resources sectors. Alpha Bronze's aim is to increase awareness for each client among the US investment community. For more info: https://www.alphabronzellc.com

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (917) 385-2160
pnigen@alphabronzellc.com

SOURCE: Alpha Bronze

ReleaseID: 598896

VANCOUVER, BC / ACCESSWIRE / July 27, 2020 / Skeena Resources Limited (TSX.V:SKE)(OTCQX:SKREF) ("Skeena" or the "Company") is pleased to announce the appointment of Mr. Greg Beard to the Board of Directors of the Company as an independent director, pending approval by the TSX Venture Exchange.

Mr. Beard has over 25 years of investment management experience. Most recently he was Global Head of Natural Resources, Senior Partner and Member of the Management Committee at Apollo Global Management in New York where he oversaw all investment activities in the energy, metals and mining and agriculture sectors. During his 10 years with Apollo, Mr. Beard managed over $11 billion of investments into the natural resources sector.

Previously, Mr. Beard was at Riverstone Holdings, an energy-focused private equity firm, as a founding member and managing director. He began his career as a financial analyst at Goldman Sachs, where he played an active role in principal investment activities. Mr. Beard currently serves on the board of directors of DoublePoint Energy and EP Energy. Mr. Beard received his Bachelor of Arts degree from the University of Illinois at Urbana.

Skeena's CEO, Walter Coles Jr. commented, "As Skeena transitions from an exploration company toward development and eventually mine production, we are fortunate to have someone of Greg's caliber join our Board. His broad business background in the natural resource sector will undoubtedly benefit the company and our shareholders as we chart our growth strategy for the months and years ahead."

The Board of Directors has granted Mr. Beard 300,000 incentive stock options. The options will have a term of 5 years, expiring on July 27, 2025. The options shall vest over a 24-month period with one third of the options vesting immediately, one third after 12 months and one third after 24 months. Each option will allow the holder to purchase one common share in the Company at a price of C$2.92. Any shares issued on the exercise of these stock options will be subject to a four month hold period, calculated from the date of the option grant.

About Skeena

Skeena Resources Limited is a junior mining company focused on developing prospective precious metal properties in the Golden Triangle of northwest British Columbia, Canada. The Company's flagship project is the Eskay Creek gold-silver mine. Skeena is also exploring the past-producing Snip gold mine.

On behalf of the Board of Directors of Skeena Resources Limited,

Walter Coles Jr.

President & CEO

Cautionary note regarding forward-looking statements

Certain statements made and information contained herein may constitute "forward looking information" and "forward looking statements" within the meaning of applicable Canadian and United States securities legislation. These statements and information are based on facts currently available to the Company and there is no assurance that actual results will meet management's expectations. Forward-looking statements and information may be identified by such terms as "anticipates", "believes", "targets", "estimates", "plans", "expects", "may", "will", "could" or "would". Forward-looking statements and information contained herein are based on certain factors and assumptions regarding, among other things, the estimation of mineral resources and reserves, the realization of resource and reserve estimates, metal prices, taxation, the estimation, timing and amount of future exploration and development, capital and operating costs, the availability of financing, the receipt of regulatory approvals, environmental risks, title disputes and other matters. While the Company considers its assumptions to be reasonable as of the date hereof, forward-looking statements and information are not guarantees of future performance and readers should not place undue importance on such statements as actual events and results may differ materially from those described herein. The Company does not undertake to update any forward-looking statements or information except as may be required by applicable securities laws.

Neither TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Walt Coles Jr.,
President & CEO
Kelly Earle, Vice President Communications
Email: kearle@skeenaresources.com
Tel: (604) 684-8725

SOURCE: Skeena Resources Limited

ReleaseID: 598931

Article Reports Results from Independent Study Demonstrating Test's 100% Sensitivity and Specificity for IgM Antibodies and 96.7% and 97.5% Sensitivity and Specificity, Respectively, for IgG Antibodies

ENGLEWOOD, CO / ACCESSWIRE / July 27, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today shared an article published in Business Insider reporting on the performance of over sixty COVID-19 antibody tests, including the COVID-19 IgG/IgM rapid test distributed by the Company. The COVID-19 IgG/IgM rapid test cassette distributed by the Company was reported as one of the few tests with 100% sensitivity and 100% specificity in detecting SARS-CoV-2 IgM antibodies.

The Business Insider article, published July 23, 2020, is titled "A new study evaluated the accuracy of more than 60 coronavirus antibody tests. 13 were a cut above the rest."

A link to the article can be found below:

https://www.businessinsider.com/best-coronavirus-antibody-tests-ranked-by-accuracy-2020-7

The new, independent review reported in Business Insider was peer-reviewed and published in the journal Diagnostics and evaluated more than 60 serological antibody tests on the U.S. market.

A link to the Diagnostics peer-reviewed study titled "COVID-19 Serological Tests: How Well Do They Actually Perform?" can be found below:

https://www.mdpi.com/2075-4418/10/7/453/htm

Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "We continue to observe, in independently conducted studies, the robust performance characteristics of the COVID-19 IgG/IgM rapid test we licensed and now distribute. It is important that clinicians and the public remain informed about the disparity in the performance characteristics of the various serology assays. Based on the Diagnostics peer-reviewed publication it is clear we are distributing one of the best performing tests in the category and are pleased to see more independent validation of the test's clinical results."

COVID-19 IgG/IgM rapid test cassette product and purchasing information is available at aytubio.com. Product inquiries may be sent to COVID-19@aytubio.com.

The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a qualitative test for the detection and differentiation of IgM and IgG antibodies against SARS-CoV-2 in whole blood, plasma (Li+-heparin, K2-EDTA and sodium citrate), and serum. The product is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

Emergency Use Authorization of the COVID-19 IgG/IgM Rapid Test Cassette was granted by the FDA on May 29, 2020 to Healgen Scientific, LLC, the U.S. subsidiary of manufacturer Zhejiang Orient Gene Biotech, Limited. Aytu BioScience announced a U.S. distribution agreement to distribute the Zhejiang Orient Gene rapid test on March 10, 2020.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu also distributes a COVID-19 IgG/IgM rapid test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma.

Aytu also operates a subsidiary focused on consumer health, Innovus Pharmaceuticals, Inc. ("Innovus"), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human® marketing and sales platform.

Aytu's strategy is to continue building its portfolio of revenue-generating Rx and consumer health products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, the regulatory and commercial risks associated with introducing the COVID-19 rapid test, the effectiveness of the COVID-19 rapid rest, market acceptance of the National Cancer Institute or other independently conducted studies' testing results, the regulatory, clinical, and commercial risks associated with the investigational Healight device, effects of the business combination of Aytu and the Commercial Portfolio and the merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for Investors:

James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com

SOURCE: Aytu BioScience, Inc.

ReleaseID: 598975

Will Assist with Covid-19 Efforts and the Brain

JACKSON CENTER, PA / ACCESSWIRE / July 27, 2020 / Halberd Corp. (OTC PINK:HALB) announced the appointment of Carl Eller, retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association as a consultant. Mr. Eller's expertise and contacts will be leveraged as part of Halberd Corporation's work on brain injury caused by impact to the head (PTSD) and potential neurological changes associated with Covid-19. Mr. Eller has worked closely with Halberd's Chief Technical Officer, Dr. Patricio Reyes, to serve the members of the NFL Retired Players Association.

Mr. Eller, drafted in 1964 as the league's 6th pick overall by the Minnesota Vikings, became a major factor as a defensive end with the unit known as the "Purple People Eaters." Eller became a six-time Pro Bowl player who appeared in four Superbowls and is currently focused on helping former players transition into retirement. He is also a champion for raising awareness of Chronic Traumatic Encephalopathy (CTE), which is recognized as a growing problem in many professional, college, and even high school sports along with armed forces of the U.S. Military. Mr. Eller is a licensed drug and alcohol counselor, and founded a group of substance-abuse clinics in the Twin Cities called Triumph Life Centers. He obtained a college degree in Human Services from Metropolitan State University in 1994.

William A. Hartman, Chairman, President and CEO of Halberd Corporation, was quoted as saying, "Mr. Eller's work with the NFL Retired Player's Association complements the work Dr. Felder previously did toward developing a treatment for PTSD/CTE with the Department of Defense at the William Beaumont Army Medical Center at Ft. Bliss in El Paso, Texas. Halberd Corporation remains committed to continue development of the PTSD/CTE treatment along with our application of the extracorporeal treatment of diseases applied to finding a treatment for people suffering from the Cornavirus."

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133

Twitter:@HalberdC

About Halberd Corporation.

HalberdCorporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

ReleaseID: 598976

FORT LAUDERDALE, FL / ACCESSWIRE / July 27, 2020 / (OTC PINK:DNAX). DNA Brands Inc. is pleased to announce that the company has selected North Equities, an up and coming Investor Engagement marketing company, to create and manage DNA's social media platform. The service will promote company engagement with the public and shareholders.

About North Equities: The North Equities team has more than 100 years of equity experience, as well as 3 deal of the year awards in Canada. With experience in the VC world of investing and more than $2B in equity raised, they have helped more than 200 companies acquire more than 120k+ investors combined. With the perfect combination of expertise, tactics, and a track record in fundraising and marketing, North Equities has created the next evolution of investor relations.

DNA Brands (DNAX), is a Colorado holding company. At present, it owns all the IP for It's Two time award winning Energy Drink, DNA Energy. In March 2020, DNA Brands Acquired 954Solar as a wholly owned subsidiary, creating a solar digital marketing division. The company is looking to make one final acquisition (who we are currently in talks with), resulting in a Holding Company with a few operating entities, working for the benefit of shareholders.

During 2019, 954Solar did approximately $1.2 Million in contractual solar sales. Now under the DNA Brands umbrella, 954Solar is actively marketing. The company anticipates contractual sales to jump drastically in the coming months.

954Solar is also expanding as a solar digital marketing agency. The company has developed a proprietary, cutting edge automation software that markets to consumers in the solar industry. The company is now actively advertising and marketing to solar friendly states such as AZ, CA, FL, IL, NJ, NY, TX.

In addition, DNA Brands has entered into early stage discussions and negotiations with several seasoned cannabis groups (as potential partners and/or operators) to partner/acquire cannabis projects in states in which cannabis is already permitted.

"We believe that full Federal cannabis legalization is coming within the next 18-36 months." By positioning ourselves early with the appropriate partners, this will give us a major market advantage and allow us to scale quickly. Working with our investment network, efforts are continuing to mount as we move forward to closing a cannabis transaction inside of DNA. "We are looking to have a few wholly owned subsidiaries inside of DNA, working to build shareholder value," stated CEO Adrian McKenzie.

With the innovation and leadership at North Equities we believe once we start building content and create a social media presence, this will be a great way to express our message of growth through acquisitions. Stated Adrian McKenzie CEO of DNA Brands Inc.

DISCLAIMER

This press release contains statements that are "Forward-Looking" in nature (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). All Statements regarding the Company's financial position, potential, business strategy, plans and objectives for future operations are Forward-Looking statements. Many of these statements contain words such as "goal," "aims," "may," "expect," "believe," "intend," "anticipate," "estimate," "continue," "would," "exceed," "should," "steady," "plan," "potential," "dramatic," and variations of such words and similar expressions identify Forward-Looking statements, but their absence does not mean that a statement is not a Forward-Looking statement. Because Forward -Looking statements involve future risks and uncertainties, there are many factors that could cause actual results to differ materially from those expressed or implied. The Company cannot predict the actual effect these factors will have on its results and many of the factors and their effects are beyond the Company's control. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise. Given these uncertainties, you should not rely too heavily on these forward-looking statements.

Adrian McKenzie-Patasar
(561) 654-5722

info@dnabrandsinc.com

https://www.thesolarelite.com/

SOURCE: DNA Brands Inc.

ReleaseID: 599006

OTTAWA, CANADA / ACCESSWIRE / July 27, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is providing its shareholders with a management update on the Company's Annual General Meeting (AGM) of shareholders commitment to be concentrating 100% of its efforts on its drug development programs with the current focus on ARDS, Plenitude© and Reborn©. Tetra previously announced at the AGM of shareholders on June 5, 2020, management's intent to spinout Lumiera Health Innovations (formerly Tetra Natural Health). On July 23rd Tetra announced the signing of a Letter of Intent (LOI) with Mondias for the sale of this subsidiary.

Tetra's February and May 2020 prospectus financings were primarily focused on raising funds to advance the QIXLEEFTM, CAUMZTM and PPP003 drug development programs closer towards marketing approval. Each of these drugs has the potential to be a billion-dollar revenue asset at peak sales. Importantly, with the regulatory path being pursued by Tetra, the Company will benefit from a minimum of 5 years of market exclusivity for these drugs in the United States, if approved. Every clinical phase successfully achieved reduces the risk of bringing a drug to the market and creates significant value for shareholders. Pharmaceutical drug development is the core business of Tetra.

The decision by Management to divest Lumiera is designed to ensure that Tetra is focused on the development of regulated drug products that have billion-dollar market potentials. Lumiera will be able to focus on the development of OTC and natural health product markets to serve unmet market needs in the areas of pain and inflammatory conditions. Lumiera consists of highly skilled professionals who have the expertise to complete manufacturing of the market-ready retail products, as well as advertising to ensure successful product launches. With cash resources fully allocated to the advancement of drug development programs, Management has decided that investing significant marketing dollars of the Lumiera products at this time was not in the best interest of the Company. Without the significant marketing dollars to support Lumiera's product lines, these products will have a hard time penetrating the market and will not result in significant sales revenue to further support Tetra's operations. To be successful in this market segment, Tetra would have to raise at a minimum $500,000 to support marketing campaigns per product that Lumiera would launch. While this division could ultimately result in millions of dollar of sales revenue if properly funded, management believes that in its current status it does not have the ability to become a billion-dollar business compared to the drug development programs that Tetra is currently developing.

"With the current COVID-19 economy and the highly dilutive nature of equity financing at Tetra's current share price, management implemented a strategy to focus the Company's activities on the potentially billion-dollar prescription drug markets and looked to monetize or suspend all none core activities. Several research analysts have supported Management's goal to focus on Tetra's core priorities. For every million dollars spent on commercialization and marketing of Lumiera's products, Tetra is sacrificing the equivalent of approximately one month of drug development costs, thereby reducing our ability to deliver on priority milestones prior to going back to the market for future financings," commented Mr. Sabino Di Paola, CFO.

The future of Lumiera was careful assessed by Management. Options such as suspending the operations of Lumiera, as well as outright selling the Lumiera's products to other companies were considered. Still, neither of these options were as attractive as the potential divestiture to Mondias, in terms of generating potential value to our shareholders.

"The decision to enter into the LOI with Mondias was the best available option at the time and allows Tetra to use its resources to concentrate on and fund its core drug development programs. Should Tetra and Mondias enter into a definitive agreement and finalize the sale of Lumiera, Mondias will have over $2.3 million to fund the development of the Lumiera assets. This funding will provide Lumiera with the ability to take these products to market in 2020 as well as to launch significant marketing campaigns to properly support a product launch. By taking a significant interest in Mondias common shares of over 15%, Tetra will have an economic benefit from the growth of Lumiera without incurring any costs or dilution to Tetra's current shareholders. The definitive agreement, when entered into, will also provide additional financial incentives to Tetra as part of the sale of Lumiera" stated Mr. Di Paola.

Tetra graduating to the TSX is key to the continued growth of the Company as well as the ability attract new investors that would have otherwise not invested in a TSX Venture listed company. To be successful on the TSX and growing Tetra's investor base at this time involves having a clear mission and vision of a developing drug company," stated Mr. Di Paola, CFO.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSXV:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland, M.Sc., Ph.D.
Chief Executive Officer
Phone: + 1 (833) 977-7575
investors@tetrabiopharma.com

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
tetra@alphabronze.net

Media Contact:

energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
carol.levine@energipr.com

SOURCE: Tetra Bio-Pharma

ReleaseID: 598974

The amount raised was increased.

THOMPSON FALLS, MT / ACCESSWIRE / July 27, 2020 / United States Antimony Corporation (NYSE American:UAMY), today announced that it has entered into a definitive agreement with investors to raise $2,010,000.30 at a price of $0.35 per unit in a private placement. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. Each warrant has an exercise price of $0.46 per share, is exercisable six months following issuance and has a term of five and one-half years following issuance. After the placement agent fees and estimated offering expenses payable by the Company, the Company expects to receive net proceeds of approximately $1,825,000.

Roth Capital Partners is acting as the sole placement agent in this offering.

The Company intends to use the net proceeds of this offering to accelerate the production of gold and silver from the Los Juarez deposit and for working capital purposes. Concurrent with the ramp in gold and silver production from the Los Juarez deposit, the Company will commence a confirmation drill program to enhance the knowledge of the geological nature and depths of the gold and silver deposit. In addition, the Company intends to reduce costs in Mexico associated with the production of antimony oxide and antimony metal and redirect the Company's antimony focus to the ore required for the profitable production of trisulfide for the DLA and the recreational trisulfide market.

The offering is expected to close on or about July 27, 2020, subject to customary closing conditions.

The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 35 days of the closing to register the resale of the shares of common stock and shares of common stock underlying the warrants issued in the private placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About United States Antimony Corporation

US Antimony is a growing, vertically-integrated natural resource company that has production and diversified operations in precious metals, zeolite and antimony.

Forward-Looking Statements

This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events, including matters related to the Company's operations, pending contracts and future revenues, ability to execute on its increased production and installation schedules for planned capital expenditures and the size of forecasted deposits. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent filings, including Form 10-KSB with the Securities and Exchange Commission.

UNITED STATES ANTIMONY CORPORATION

PO Box 643 47 Cox Gulch Rd.
Thompson Falls, Montana 59873-0643
406-827-3523
FAX: 406-827-3543
E-Mail tfl3543@blackfoot.net

SOURCE: United States Antimony Corporation

ReleaseID: 598960

The C1000S Microturbine Will Provide Heat & Power for a Manufacturing Facility

VAN NUYS, CA / ACCESSWIRE / July 27, 2020 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that it continues to diversify its long-term microturbine rental business with a C1000 Signature Series (C1000S) microturbine rental contract for a remote manufacturing facility in Colorado.

The 5-year rental is scheduled to begin in September 2020 and was secured by Horizon Power Systems, Capstone's distribution partner in Arizona, Colorado, Idaho, Montana, New Mexico, Oklahoma, Utah, Wyoming, and Western Canada (www.horizonpowersystems.com).

"Long-term rentals are a significant opportunity for us and provide reoccurring revenue at high margins," said Darren Jamison, President and Chief Executive Officer at Capstone Turbine. "Long-term rentals and our industry-leading Factory Protection Plan (FPP) long-term service contracts help migrate Capstone towards an energy as a service model, which is a nice fit for our hi-tech microturbine technology," added Mr. Jamison.

Capstone's existing microturbine rental fleet stands at approximately 8 MW, and as part of management's focus to achieve and sustain positive Adjusted EBITDA, this fleet should continue to expand towards the company's initial fleet target of 10 MW.

According to Technavio, the global power rental market size will grow by over $992 million during 2018-2022, which will be driven by the rising demand for uninterrupted power in the next five years. The need for continuous, reliable, and quality power is increasing at a considerable rate.

The Capstone C1000S microturbine system will replace a reciprocating diesel generator and provide 1 megawatt (MW) of prime power for the remote facility. The microturbine will be fueled by clean-burning liquefied natural gas (LNG). The system will be paired with a heat exchanger and be installed in a combined heat and power (CHP) application that will allow the customer to utilize the available exhaust heat to support operations and provide hot water and space heating.

The customer ultimately chose low-emission Capstone microturbines as the ideal solution for their remote facility due to the microturbine's low maintenance, resiliency, and ability to reduce energy costs. Capstone's energy-efficient solution further reduces the operation's environmental footprint while also helping the customer meet sustainability goals.

"The Capstone microturbine solution fits perfectly with the critical needs of this customer's remote operations as they were looking for a scalable solution that can reduce costs and improve efficiency," said Sam Henry, President, Horizon Power Systems. "Our customers demand reliable on-site power, and in partnership with Capstone Turbine, we are able to provide our customers with one of the most reliable on-site power generation solutions available today," concluded Mr. Henry.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today's multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems, for more information, contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as "expects," "believes," "objective," "intend," "targeted," "plan" and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone's filings with the Securities and Exchange Commission that may cause Capstone's actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

"Capstone" and "Capstone Microturbine" are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT: Capstone Turbine Corporation

Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 598970